Medication-assisted treatment (MAT) combines FDA-approved medications with counselling and behavioural therapies to treat opioid use disorder. The three primary medications are methadone (a full mu-opioid agonist), buprenorphine (a partial agonist, often combined with naloxone as Suboxone), and naltrexone (an opioid antagonist, available as monthly injection Vivitrol). Research consistently shows that MAT reduces opioid use, overdose deaths, criminal activity, and infectious disease transmission while improving treatment retention and social functioning. MAT is not “replacing one addiction with another” but rather a clinically validated approach to stabilising brain chemistry that has been disrupted by chronic opioid exposure.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
“One of the most persistent barriers to opioid recovery is the misconception that medication-assisted treatment is simply substituting one substance for another,” says Dr. Ponlawat Pitsuwan. “In our clinical experience at Phuket Island Rehab, patients who receive appropriately managed MAT as part of a comprehensive treatment programme achieve significantly better outcomes than those who attempt abstinence-only approaches. The medications normalise brain function; they do not create the euphoric highs or destructive behaviours that define active addiction.”
Understanding How Opioids Change the Brain
To understand why MAT works, it is essential to understand what chronic opioid use does to the brain. Opioids bind to mu-opioid receptors (MOR) in the brainstem, limbic system, and spinal cord, triggering dopamine release in the nucleus accumbens and suppressing pain signalling. With repeated exposure, the brain adapts by downregulating these receptors and reducing its own production of endogenous opioids such as endorphins and enkephalins. This neuroadaptation creates a state where the brain functions abnormally without the external opioid supply.
When the opioid is removed abruptly, the depleted system produces intense withdrawal symptoms: severe anxiety, muscle pain, insomnia, nausea, diarrhoea, and an overwhelming craving to use again. This is not a failure of willpower but a physiological response to a brain that has been chemically restructured. MAT medications address this by either partially or fully activating the same receptors in a controlled, stable manner (methadone and buprenorphine) or by blocking the receptors so opioids cannot produce their effects (naltrexone).
The Three MAT Medications Compared
| Characteristic | Methadone | Buprenorphine (Suboxone) | Naltrexone (Vivitrol) |
|---|---|---|---|
| Mechanism | Full mu-opioid agonist | Partial mu-opioid agonist + kappa antagonist | Mu-opioid antagonist |
| Administration | Daily oral liquid (clinic-observed) | Sublingual film/tablet or monthly injection (Sublocade) | Monthly intramuscular injection or daily oral tablet |
| Prescribing setting | Licensed opioid treatment programme (OTP) only | Any qualified physician (office-based) | Any licensed prescriber |
| Withdrawal required before starting | No | Yes (moderate withdrawal, or micro-dosing protocol) | Yes (7 to 14 days opioid-free) |
| Overdose risk if misused | Higher (full agonist, no ceiling effect) | Lower (ceiling effect on respiratory depression) | None (antagonist, no opioid effect) |
| Reduction in overdose mortality | Up to 50% (Cochrane review data) | Up to 50% (comparable to methadone) | Significant (blocks opioid effects entirely) |
| Treatment retention at 12 months | Highest among MAT medications | Moderate to high | Lower (requires full detoxification first) |
Methadone: The Gold Standard for Severe Opioid Dependence
Methadone has been used for opioid addiction treatment since the 1960s and has the longest evidence base of any MAT medication. It is a synthetic full mu-opioid agonist with a long half-life of 24 to 36 hours, which allows once-daily dosing and provides stable blood levels that prevent both withdrawal symptoms and cravings. Unlike heroin or fentanyl, which produce rapid peaks and troughs in opioid receptor activation, methadone provides a steady-state occupancy that normalises brain function without producing significant euphoria at therapeutic doses.
Methadone is dispensed through licensed opioid treatment programmes (OTPs), where patients initially attend daily for observed dosing. As they demonstrate stability, they earn take-home privileges. This structured approach provides accountability and regular clinical contact, which benefits patients with severe dependence and limited social stability. Methadone maintenance has been shown to reduce illicit opioid use by 33 to 69%, reduce criminal activity, decrease HIV and hepatitis C transmission through reduced needle sharing, and halve the risk of overdose death.
The primary concerns with methadone are its potential for respiratory depression at higher doses (particularly during the induction period), QTc interval prolongation (a cardiac conduction effect that can cause arrhythmia), and drug interactions with medications metabolised by CYP3A4 and CYP2B6. These risks are managed through careful dose titration, ECG monitoring, and awareness of the patient’s full medication profile.
Buprenorphine: Accessible and Safer
Buprenorphine is a partial mu-opioid agonist, meaning it activates the mu receptor but to a lesser degree than full agonists like methadone or heroin. This partial activation produces a ceiling effect: beyond a certain dose, additional buprenorphine does not produce greater respiratory depression, making it significantly safer in overdose than methadone. Buprenorphine also has strong receptor binding affinity, meaning it effectively blocks other opioids from accessing the receptor, which reduces the reward of using opioids on top of the medication.
The most widely prescribed formulation is Suboxone, which combines buprenorphine with naloxone in a 4:1 ratio. The naloxone component is included to deter injection misuse: when taken sublingually as directed, naloxone has minimal bioavailability and no clinical effect, but if the tablet or film is dissolved and injected, the naloxone becomes active and precipitates immediate withdrawal. Sublocade is a newer monthly subcutaneous injection formulation that provides sustained buprenorphine levels without the need for daily dosing, improving adherence and reducing diversion risk.
The main clinical challenge with buprenorphine is induction. Because it is a partial agonist with high binding affinity, initiating buprenorphine while significant levels of full agonists remain on the receptor can precipitate severe withdrawal. Traditional protocols require waiting until the patient scores 12 or higher on the Clinical Opiate Withdrawal Scale (COWS) before the first dose. For fentanyl-dependent patients, where the drug lingers in fat tissue, micro-dosing induction (the Bernese method) has become an increasingly preferred approach, allowing gradual receptor transition without the precipitated withdrawal risk.
Naltrexone: The Abstinence-Based Option
Naltrexone works differently from methadone and buprenorphine. Rather than activating opioid receptors, it blocks them entirely. A person on naltrexone who uses an opioid will experience no euphoria, no pain relief, and no respiratory depression from that opioid, because naltrexone occupies the receptor and prevents the opioid from binding. This makes it an effective relapse prevention tool for highly motivated individuals who have completed detoxification.
The monthly injectable formulation (Vivitrol) is preferred over daily oral naltrexone because it eliminates the compliance problem of daily pill-taking. A single intramuscular injection provides 30 days of continuous opioid blockade. However, naltrexone has a significant limitation: the patient must be fully detoxified and opioid-free for at least 7 to 14 days before starting, as administering naltrexone to someone with opioids in their system will precipitate severe withdrawal. This detoxification requirement is a significant barrier, as many patients relapse during the waiting period before naltrexone can be initiated.
Clinical insight: At Phuket Island Rehab, the choice of MAT medication is individualised based on the severity of dependence, the patient’s treatment history, co-occurring medical and psychiatric conditions, and their social circumstances. There is no universally superior medication. What matters is that the patient receives appropriate pharmacological support alongside psychosocial interventions rather than being expected to achieve recovery through willpower alone.
Addressing the “Replacement” Myth
The most damaging misconception about MAT is that it replaces one addiction with another. This reflects a misunderstanding of both addiction and how these medications work. Addiction is characterised by compulsive use despite harm, loss of control, and continued use despite negative consequences. MAT medications, when taken as prescribed, produce none of these features. They do not cause euphoria, impaired functioning, or compulsive use. They stabilise brain chemistry so the person can engage in the psychological and social work of recovery.
The analogy to other chronic diseases is instructive. No one would suggest that a person with Type 1 diabetes is “addicted to insulin” or that taking antihypertensive medication for high blood pressure is “replacing one problem with another.” These medications correct a physiological dysfunction, and so do MAT medications for opioid use disorder. The World Health Organization, the National Institute on Drug Abuse, the Substance Abuse and Mental Health Services Administration, and every major medical body endorse MAT as the evidence-based standard of care for opioid use disorder.
When Substance Use Has Become More Than Occasional
Opioid use disorder develops along a continuum that often begins with legitimate medical use or experimental recreational use and progresses through tolerance, physical dependence, and compulsive use. The DSM-5 defines opioid use disorder by the presence of at least two of eleven criteria within a twelve-month period, including using larger amounts than intended, persistent desire to cut down without success, craving, failure to fulfil obligations, continued use despite social or interpersonal problems, tolerance, and withdrawal.
If you recognise these patterns in your own substance use, it is important to understand that opioid use disorder is a chronic, relapsing brain condition with effective, evidence-based treatments. Early intervention with MAT significantly improves the likelihood of sustained recovery. Residential treatment programmes like Phuket Island Rehab provide the comprehensive environment needed to initiate MAT, manage withdrawal safely, address co-occurring mental health conditions, and build the coping strategies and relapse prevention skills necessary for long-term sobriety.
Summary
Medication-assisted treatment is the most effective intervention available for opioid use disorder. Methadone, buprenorphine, and naltrexone each address different aspects of opioid dependence and are appropriate for different clinical situations. The evidence is unequivocal: MAT reduces overdose deaths, improves treatment retention, decreases illicit drug use, and allows people to rebuild their lives. The stigma surrounding MAT remains a barrier to access, but it is contradicted by decades of clinical research and endorsed by every major health organisation worldwide.
“The question should never be whether someone should use medication in their recovery from opioid dependence,” says Dr. Ponlawat Pitsuwan. “The question should be which medication, at what dose, combined with which therapeutic supports, will give this individual the best chance of sustained recovery. Every patient who walks through our doors at Phuket Island Rehab deserves a treatment plan that reflects the current science, not outdated ideology about what recovery should look like.”
Frequently Asked Questions
How long do people stay on MAT medications?
There is no fixed duration for MAT. Current clinical guidelines recommend that treatment continue for as long as the patient continues to benefit, which for many people means years or indefinitely. Research shows that patients who discontinue MAT prematurely have significantly higher relapse and overdose rates than those who continue. The decision to taper off MAT should be made collaboratively between the patient and their clinician, based on clinical stability, not arbitrary timelines or external pressure.
Can you still feel pain while on buprenorphine or methadone?
Yes. Patients on MAT retain the ability to feel pain, though their pain management may require modifications. For methadone patients, the analgesic effect of their maintenance dose typically lasts only 6 to 8 hours (shorter than the 24 to 36 hour duration for withdrawal suppression), so supplemental analgesia may be needed. For buprenorphine patients, the partial agonist properties may complicate acute pain management, and clinicians may need to use higher doses of full agonists or switch temporarily to alternative analgesic strategies for surgical or acute pain situations.
Is Suboxone safe during pregnancy?
Buprenorphine monotherapy (without naloxone) is considered the preferred MAT option during pregnancy, based on the MOTHER trial, which found that buprenorphine was associated with shorter neonatal abstinence syndrome (NAS) duration compared to methadone. Methadone is also used safely during pregnancy and has a longer track record. Both are significantly safer than untreated opioid use disorder during pregnancy, which carries risks of preterm birth, placental abruption, fetal distress, and overdose death. The naloxone component in Suboxone is generally avoided during pregnancy as a precaution, though sublingual absorption makes systemic naloxone exposure minimal.
Does MAT show up on a drug test?
Standard workplace drug panels typically test for opiates (morphine, codeine) and do not detect buprenorphine or methadone, which require specific assays. However, extended panels used in clinical or legal settings may include tests for buprenorphine and methadone specifically. Naltrexone is not an opioid and does not appear on any standard drug test. Patients on MAT should inform their prescriber and any testing authority that they are receiving prescribed medication, as documentation of a legitimate prescription typically resolves any positive result.
Can you drink alcohol while on MAT?
Alcohol use while on methadone or buprenorphine is strongly discouraged and potentially dangerous. Both medications cause central nervous system depression, and alcohol compounds this effect, increasing the risk of respiratory depression, sedation, and overdose. Methadone is particularly risky in combination with alcohol because both are full CNS depressants with additive effects. Buprenorphine’s ceiling effect on respiratory depression provides some safety margin, but alcohol can override this protection at higher consumption levels. Naltrexone does not interact dangerously with alcohol at the pharmacological level, but clinicians still counsel against alcohol use as part of a comprehensive recovery programme.
What happens if you use opioids while taking naltrexone?
If a person on naltrexone uses an opioid, they will experience little to no effect from the opioid because naltrexone occupies the mu-opioid receptors and prevents binding. There is no euphoria, no pain relief, and no respiratory depression. However, there is a serious danger: if a person attempts to override the naltrexone blockade by using very large amounts of opioids, they risk severe respiratory depression once the naltrexone wears off and the accumulated opioid dose takes effect. After discontinuing naltrexone, patients are at heightened overdose risk because their tolerance has decreased and any return to prior use levels can be fatal.
Sources
Substance Abuse and Mental Health Services Administration (SAMHSA). “Medications for Opioid Use Disorder.” Treatment Improvement Protocol (TIP) Series 63. samhsa.gov
National Institute on Drug Abuse (NIDA). “Medications to Treat Opioid Use Disorder Research Report.” National Institutes of Health. drugabuse.gov
World Health Organization. “Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence.” who.int
Medication-assisted treatment · MAT · Methadone · Buprenorphine · Suboxone · Sublocade · Naltrexone · Vivitrol · Naloxone · Mu-opioid receptor · Partial agonist · Full agonist · Opioid antagonist · COWS scale · Bernese method · Precipitated withdrawal · CYP3A4 · CYP2B6 · QTc prolongation · Opioid use disorder · DSM-5 · Phuket Island Rehab